Abstract
Patients (pts) with cardiomyopathy (CM) and impaired ejection fraction (EF) have increased risk of ventricular tachycardia or fibrillation (VT/VF). The wearable cardioverter defibrillator (WCD) protects pts with VT/VF until their response to guideline directed medical therapy (GDMT) can be
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
